3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Potent H+,K+-ATPase Inhibitor for Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) is a potent and selective inhibitor of the gastric proton pump H+,K+-ATPase, with an IC₅₀ of 5.8 μM under standard in vitro conditions (APExBIO). It demonstrates high efficacy against histamine-induced acid formation with an IC₅₀ of 0.16 μM. Its purity (≥98%) is confirmed by HPLC and NMR, ensuring reproducibility in research settings. The compound is insoluble in water/ethanol, but dissolves in DMSO at ≥17.27 mg/mL. It is recommended for research on gastric acid-related disorders and the proton pump inhibition pathway, but is not suitable for diagnostic or clinical use (Kong et al., 2025).

Biological Rationale

Gastric acid secretion is mediated by the H+,K+-ATPase enzyme, a membrane-bound proton pump localized to parietal cells of the gastric mucosa. Dysregulated acid secretion is a key driver of peptic ulcer disease and other gastric acid-related disorders. Pharmacological inhibition of H+,K+-ATPase is a validated approach for controlling gastric acidity in both experimental and translational research models (see mechanistic review). 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, as supplied by APExBIO, provides a reproducible and well-characterized tool for dissecting the molecular basis of gastric acid secretion and testing antiulcer interventions. Unlike less-specific agents, this compound targets the final common pathway of acid secretion, enabling precise modulation and mechanistic studies.

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

The compound acts as a competitive inhibitor of the H+,K+-ATPase enzyme, blocking the exchange of intracellular H⁺ for extracellular K⁺ ions. This prevents acidification of the gastric lumen. In cell-based assays, the compound demonstrates an IC₅₀ of 5.8 μM for direct H+,K+-ATPase inhibition. For secondary endpoints, such as histamine-induced gastric acid formation, the compound achieves an IC₅₀ of 0.16 μM, suggesting high potency in physiologically relevant conditions (APExBIO). The inhibitor does not irreversibly block the enzyme, which allows for controlled, titratable effects in short-term experiments. Its mechanism parallels that of clinical proton pump inhibitors, but it is optimized for preclinical research and is not intended for therapeutic use.

Evidence & Benchmarks

• Demonstrates H+,K+-ATPase inhibition with IC₅₀ = 5.8 μM in standard in vitro enzyme assays (APExBIO).
• Exhibits potent antisecretory action in histamine-stimulated acid formation models (IC₅₀ = 0.16 μM) (APExBIO).
• Supplied with a purity of ≥98% (HPLC and NMR-verified) for maximal reproducibility (APExBIO).
• Stability data indicate optimal storage at –20°C; compound remains stable as a solid for ≥12 months, but should not be stored long-term in solution (APExBIO).
• Solubility in DMSO is ≥17.27 mg/mL; insoluble in water and ethanol, requiring careful solvent selection for in vitro and in vivo protocols (APExBIO).
• Supports robust cell-based and ex vivo gastric acid secretion assays, as shown in advanced protocol guides (protocol resource).

Applications, Limits & Misconceptions

The compound is engineered for research applications, including:

• Mechanistic studies of the proton pump inhibition pathway.
• Modeling of peptic ulcer disease and gastric acid-related disorders in vitro and in vivo (extended workflow guide).
• Evaluation of antiulcer activity in pharmacological screens.
• Integration with imaging, behavioral, or omics endpoints in multi-modal experimental designs (Kong et al., 2025).

However, several boundaries apply:

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use; for laboratory research only.
• Ineffective in models where acid secretion is not H+,K+-ATPase-dependent.
• May precipitate or show reduced activity in aqueous or ethanol-based media due to insolubility.
• Long-term storage in DMSO or other solvents results in degradation; use freshly prepared solutions.
• Cannot be used to probe other ATPases (e.g., Na+,K+-ATPase) due to its selectivity profile.

This article extends the mechanistic context provided in 'Revolutionizing Gastric Acid Secretion Research' by supplying recent stability and solubility benchmarks, and details practical limitations that are often overlooked in earlier reviews.

Workflow Integration & Parameters

For optimal results, dissolve the solid compound in DMSO (up to ≥17.27 mg/mL) and dilute as needed into assay buffers, ensuring final DMSO concentrations remain compatible with biological systems. For cell-based or ex vivo tissue studies, titrate concentrations from 0.1–10 μM to identify the potency window. Store all dry aliquots at –20°C, protected from light and moisture. Do not store working solutions beyond 24–48 hours, even at –20°C. Regularly verify purity and identity by HPLC or NMR if re-used over multiple experimental cycles. Protocols from 'Optimizing Gastric Acid Secretion Research with a Potent H+,K+-ATPase Inhibitor' offer troubleshooting steps for compound handling and integration into multi-well formats. This article provides updated solubility and stability data, enabling finer control over assay reproducibility compared to prior literature.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) stands as a gold-standard tool for H+,K+-ATPase inhibition in gastric acid secretion research. Its validated potency, stability, and purity support reproducible results in peptic ulcer and antiulcer activity models. Ongoing development of advanced imaging and gut–liver–brain axis models, as highlighted by Kong et al. (2025), will further extend the utility of selective proton pump inhibitors in systems biology and translational research. Researchers should consult the A2845 product dossier for the latest benchmarks and handling instructions.